GlassScriptPhysician profile
Mandeep Garewal
NPI 1700997707
$12,730.34
in general payments reported to CMS, 2019-2025
64 companies · $2,532 in 2025
The $2,532 reported for 2025 was more than what 75% of Diagnostic Neuroimaging (Psychiatry & Neurology) providers received nationally (typical 2025 total: $1,744).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $925 · 2021: $1,474 · 2022: $2,379 · 2023: $1,540 · 2024: $1,419 · 2025: $2,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,324 · Education: $159 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,323.86 |
| Education | $159.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,956.10 | 2019-2025 | |
| Abbvie INC. | $1,555.57 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $816.47 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $562.82 | 2022-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $453.99 | 2021-2025 | |
| Mdd US Operations, LLC | $444.38 | 2019-2025 | Gocovri |
| Emd Serono, INC. | $433.10 | 2019-2023 | Mavenclad |
| Eisai INC. | $410.56 | 2019-2025 | |
| Inspire Medical Systems, INC. | $409.88 | 2021-2025 | Inspire |
| Livanova USA, INC. | $406.13 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $392.11 | 2021-2025 | Amyvid, Kisunla, Zepbound |
| Genzyme Corporation | $306.77 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.07 | 2023-2025 | Hyqvia |
| Tanabe Pharma America, INC. | $249.21 | 2021-2025 | Radicava |
| Argenx US, INC. | $248.78 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $227.39 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $226.20 | 2021-2025 | Givlaari, Amvuttra |
| Amneal Pharmaceuticals LLC | $219.82 | 2021-2025 | Crexont, Ongentys |
| Sk Life Science, INC. | $207.35 | 2020-2025 | |
| Ucb, INC. | $200.96 | 2022-2025 | Rystiggo, Briviact |
| Sunovion Pharmaceuticals INC. | $194.84 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $160.72 | 2019-2021 | |
| Acorda Therapeutics, INC | $160.03 | 2019-2023 | Inbrija |
| Corium, LLC | $155.89 | 2022-2023 | Adlarity |
| Jazz Pharmaceuticals INC. | $140.61 | 2019-2023 | Epidiolex |
| Catalyst Pharmaceuticals, INC. | $138.55 | 2023-2025 | Firdapse |
| Alexion Pharmaceuticals, INC. | $125.31 | 2019-2024 | Ultomiris |
| Amgen INC. | $125.15 | 2021-2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $125.08 | 2023-2025 | Rexulti |
| Biogen, INC. | $124.61 | 2021-2025 | Vumerity, Avonex, Plegridy |
| Csl Behring | $123.92 | 2020-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $100.71 | 2020-2024 | Nuplazid |
| Lundbeck LLC | $89.83 | 2019-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $88.70 | 2019-2025 | Qelbree |
| Genentech USA, INC. | $62.38 | 2020-2024 | Ocrevus |
| Allergan, INC. | $53.52 | 2019-2020 | |
| Celgene Corporation | $52.78 | 2021-2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $52.44 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $50.42 | 2023-2024 | Ztlido |
| Idorsia Pharmaceuticals US INC | $50.09 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $48.08 | 2020-2021 | |
| Grifols USA, LLC | $46.15 | 2019-2025 | Gamunex-C |
| Octapharma USA, INC. | $41.03 | 2024-2025 | Panzyga |
| Harmony Biosciences LLC | $40.43 | 2021-2022 | |
| Greenwich Biosciences, INC. | $34.19 | 2020-2021 | |
| Avion Pharmaceuticals | $33.19 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.71 | 2022 | |
| Kyowa Kirin, INC. | $24.78 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $23.79 | 2025 | Lumryz |
| Medtronic, INC. | $22.28 | 2025 | Intellis Adaptivestim |
| Mallinckrodt Hospital Products INC. | $20.60 | 2022 | |
| Chiesi USA, INC. | $19.61 | 2019 | |
| Impel Pharmaceuticals INC. | $18.52 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $17.46 | 2022 | |
| Janssen Biotech, INC. | $16.19 | 2025 | |
| Fisher & Paykel Healthcare INC | $16.12 | 2025 | Fisher & Paykel Healthcare |
| Merck Sharp & Dohme LLC | $16.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.41 | 2022 | |
| Zoll Respicardia, INC. | $15.24 | 2023 | Remede System |
| Axsome Therapeutics, INC. | $14.34 | 2024 | Sunosi |
| C2n Diagnostics, LLC | $14.00 | 2025 | Precivityad2 |
| Arbor Pharmaceuticals, INC. | $12.10 | 2021 | |
| Avanir Pharmaceuticals, INC. | $10.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Garewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.